Clinical Trial News and Research

RSS

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire plc, the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).

23 Jul 2014

University of Leicester receives funding from two Masonic charities for heart study

A University of Leicester research project has received vital philanthropic funding for the second year from two Masonic charities.

23 Jul 2014

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer.

23 Jul 2014

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

23 Jul 2014

Viruses designed to kill cancer cells could boost effectiveness of chemotherapy to arms, legs

Viruses designed to target and kill cancer cells could boost the effectiveness of chemotherapy to the arms and legs and help avoid amputation, a new study reports.

22 Jul 2014

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076.

21 Jul 2014

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C.

21 Jul 2014

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils.

19 Jul 2014

Brain network measures placebo effects in Parkinson's disease patients

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.

19 Jul 2014

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine.

18 Jul 2014

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

18 Jul 2014

Researchers make significant breakthrough that may benefit patients with bowel cancer

Researchers at Queen's University have made a significant breakthrough that may benefit patients with bowel cancer.

18 Jul 2014

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

The U.S. affiliate of Ipsen today announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline Autogel / Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) achieved statistically significant prolongation of progression free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

17 Jul 2014

Ruthigen treats first human subjects with leading drug candidate RUT58-60

Ruthigen, Inc., today announced that it has treated the first human subjects with its leading drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August 2014.

17 Jul 2014

Study examines mechanism of bone-protective properties of California dried plums

Fifty-seven million Americans suffer from low bone density or osteoporosis, a disease which causes bones to become so weak and brittle that even a minor fall or other stresses may cause fractures.

17 Jul 2014

Cholesterol-lowering statins may prolong lives of people with diabetic cardiovascular disease

Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. In fact, at least 65 percent of people with diabetes die from some form of heart disease or stroke, according to the American Heart Association.

17 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Significant percentage of completed drug clinical trials are not disclosed to public

A significant percentage of completed drug clinical trials, especially those funded by industry, are not disclosed to the public, years after being completed-a trend that "threatens the validity of the clinical research literature in the U.S.," according to a study led by a Boston University School of Public Health (BUSPH) researcher.

16 Jul 2014

Tamoxifen gel stops breast cancer growth without causing dangerous side effects

A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects that deter some women from taking it, according to new Northwestern Medicine- research.

16 Jul 2014

Urge incontinence therapy may relieve stress incontinence

Anticholinergic medication appears to be effective as a treatment for stress and mixed urinary incontinence, results of a small clinical trial indicate.

15 Jul 2014

Clinical Trial News and Research

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

University of Leicester receives funding from two Masonic charities for heart study

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Advaxis, MedImmune team up for immuno-oncology clinical trial

Viruses designed to kill cancer cells could boost effectiveness of chemotherapy to arms, legs

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Brain network measures placebo effects in Parkinson's disease patients

Phase II study reveals potential biomarker for HIV vaccine

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

Researchers make significant breakthrough that may benefit patients with bowel cancer

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Ruthigen treats first human subjects with leading drug candidate RUT58-60

Study examines mechanism of bone-protective properties of California dried plums

Cholesterol-lowering statins may prolong lives of people with diabetic cardiovascular disease

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Significant percentage of completed drug clinical trials are not disclosed to public

Tamoxifen gel stops breast cancer growth without causing dangerous side effects

Urge incontinence therapy may relieve stress incontinence

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer